Topoisomerase Inhibitors Market 2019 Top Companies- F. Hoffmann-La Roche Ltd, Mundipharma EDO GmbH, Purdue Pharma L.P.

Topoisomerase Inhibitors Market 2019, A recent report published by Data Bridge Market Research provides a unique guidance in thoughtful details regarding the development factors, used a top-down and bottom-up approach to keep it error-free and accurate. The researchers have used primary and secondary methodologies to collect data and its analysis.

Market Segment by Companies, this report covers F. Hoffmann-La Roche Ltd, Mundipharma EDO GmbH, Purdue Pharma L.P., Debiopharm Group, Ipsen Pharma, TopoGEN, Inc., Nektar, Hikma Pharmaceuticals PLC, Fresenius Health Care Group, Mylan N.V., Pfizer Inc., Merrimack Pharmaceuticals, VBShilpa, others

Click More Info| Get Sample Report @


Topoisomerase inhibitors belong to chemotherapy drugs class which inhibits topoisomerase proteins which controls the changes in DNA structure during cell cycle. These drugs function by targeting the ligation step of cell cycle. The growth and proliferation of cancer cells is stopped by these drugs. Topoisomerase inhibitors are also used as antibacterial drugs. These drugs are used for several types of cancers such as lung cancer, leukemia, testicular cancers among others.

According to American Cancer Society, the incidence of lung cancer in 2019 accounts for an estimated of 228,150 new cases in the United States. Lung cancer is the most common type of cancer which is treated by topoisomerase inhibitors.

 Segmentation of the market

  • By Drugs Classification ( Topoisomerase I Inhibitors, Topoisomerase II Inhibitors),
  • Application (Testicular Cancer, Leukemia, Lung Cancer, Others),
  • Drugs (Etoposide, Irinotecan, Topotecan, Others),
  • Route of Administration (Oral, Injectable, Others),
  • End Users (Hospitals, Homecare, Specialty Clinics, Others),
  • Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)

Geographical landscape covered in the report

This TOPOISOMERASE INHIBITORS report covers a geographical landscape including the region like North America, South America, Asia and Pacific region, Middle East and Africa and Europe.  Other vital key regions are also taken into account while developing this report.

For Early Buyers | Get Up to 30% Discount on This Report:

Questions related to the report:

  • What does this TOPOISOMERASE INHIBITORS market research report offers?

This TOPOISOMERASE INHIBITORS report helps you to find about the key industry trends, threats and opportunities. It informs your decision for marketing strategy and planning.  The most important its TOPOISOMERASE INHIBITORS report helps you to quickly build competitive intelligence in this rapidly changing market.

  • Which techniques are utilized to overcome the threats?

Before creating this TOPOISOMERASE INHIBITORS report different type of tools and techniques such as SWOT analysis, Porter’s five analysis, Pestle Analysis, Industry chain analysis are utilized which helps the readers to overcome the threats of the market.

Market Drivers and Restraints

  • Increasing awareness about novel topoisomerase inhibitor drugs for chemotherapy will also expand the market growth
  • Rising R&D activity of novel drugs is one of the major driver for growth of market
  • High cost of chemotherapies is a factor restricting the market growth
  • Side effects of chemotherapy is one of the major factor hindering this market growth

Key Developments in the Market:

In March 2019, F. Hoffmann-La Roche Ltd received the U. S. FDA approval for combination therapy Tecentriq (atezolizumab) with carboplatin and etoposide (topoisomerase inhibitor) for treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). This combination therapy brings a bright targeted treatment option for ES-SCLC and the approval of this therapy will expand the oncology market of F. Hoffmann-La Roche

In February 2019, Mundipharma EDO GmbH and Purdue Pharma L.P. announced the grant of Orphan Drug designation from the U. S. FDA to Etoposide toniribate for treatment of patients with biliary tract cancer (cholangiocarcinoma). This designation provides reduced approval fees and 10 years marketing exclusivity of etoposide toniribate for treatment of cholangiocarcinoma to the companies after the approval

Major Points Covered in Table of Contents:

  • Global Topoisomerase Inhibitors Platforms Market Overview
  • Economic Impact on Industry
  • Market Competition by Manufacturers
  • Production, Revenue (Value) by Region
  • Supply (Production), Consumption, Export, Import by Regions
  • Production, Revenue (Value), Price Trend by Type
  • Global Topoisomerase Inhibitors Platforms Market Analysis by Application
  • Manufacturing Cost Analysis
  • Industrial Chain, Sourcing Strategy and Downstream Buyers
  • Marketing Strategy Analysis, Distributors/Traders
  • Market Effect Factors Analysis
  • Global Topoisomerase Inhibitors Platforms Market Forecast

Read Complete Details with TOC @                   


This TOPOISOMERASE INHIBITORS research report gives the outcome that matters most to the client. The research carried out in this report suggests what is going to be beneficial and how the report will help the business to grow.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *